Lisocabtagene Maraleucel治疗复发/难治性套细胞淋巴瘤:TRANSCEND NHL 001 I期多中心无缝设计研究套细胞淋巴瘤队列的主要分析
TRANSCEND NHL 001 I期无缝设计研究套细胞淋巴瘤队列主要分析,104例患者白细胞采集,88例接受liso-cel输注,疗效集83例。客观缓解率83.1%,完全缓解率72.3%,中位缓解持续时间15.7个月,中位无进展生存期15.3个月。≥3级细胞因子释放综合征发生率1%,≥3级神经事件发生率9%,≥3级感染发生率15%。
要点
- 复发/难治性套细胞淋巴瘤患者接受liso-cel后完全缓解率达72.3%。
- 中位缓解持续时间15.7个月,中位无进展生存期15.3个月。
- ≥3级细胞因子释放综合征发生率1%,≥3级神经事件发生率9%。
核心结论
- liso-cel在既往重度治疗的复发/难治性套细胞淋巴瘤患者中显示出高完全缓解率和深度持久缓解,≥3级细胞因子释放综合征、神经事件和感染发生率低。
研究设计与样本
- I期多中心无缝设计TRANSCEND NHL 001研究(NCT02631044)的套细胞淋巴瘤队列主要分析。
- 入组患者为既往接受≥2线治疗(包括Bruton酪氨酸激酶抑制剂、烷化剂和CD20靶向药物)的复发/难治性套细胞淋巴瘤患者。
- liso-cel目标剂量水平为50×10^6(DL1)或100×10^6(DL2)嵌合抗原受体阳性T细胞。
- 104例患者进行了白细胞采集,88例接受了liso-cel输注;疗效集83例(DL1+DL2)。
主要发现
- 疗效集(n=83)客观缓解率为83.1%(95% CI,73.3至90.5),完全缓解率为72.3%(95% CI,61.4至81.6)。
- 中位缓解持续时间为15.7个月(95% CI,6.2至24.0),中位无进展生存期为15.3个月(95% CI,6.6至24.9)。
- 最常见≥3级治疗中出现的不良事件为中性粒细胞减少(56%)、贫血(37.5%)和血小板减少(25%)。
- 细胞因子释放综合征发生率为61%(3/4级1%;5级0),神经事件发生率为31%(3/4级9%;5级0),≥3级感染发生率为15%,持续性血细胞减少发生率为40%。
- 患者中位既往治疗线数为3线(范围1-11),30%接受过≥5线既往治疗,73%年龄≥65岁,69%为难治性疾病,53%为BTKi难治性疾病,23%有TP53突变,8%有继发性中枢神经系统淋巴瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the primary analysis results from the mantle cell lymphoma (MCL) cohort of the phase I seamless design TRANSCEND NHL 001 (ClinicalTrials.gov identifier: NCT02631044) study. METHODS: Patients with relapsed/refractory (R/R) MCL after ≥two lines of previous therapy, including a Bruton tyrosine kinase inhibitor (BTKi), an alkylating agent, and a CD20-targeted agent, received lisocabtagene maraleucel (liso-cel) at a target dose level (DL) of 50 × 106 (DL1) or 100 × 106 (DL2) chimeric antigen receptor-positive T cells. Primary end points were adverse events (AEs), dose-limiting toxicities, and objective response rate (ORR) by independent review committee per Lugano criteria. RESULTS: Of 104 leukapheresed patients, liso-cel was infused into 88. Median (range) number of previous lines of therapy was three (1-11) with 30% receiving ≥five previous lines of therapy, 73% of patients were age 65 years and older, 69% had refractory disease, 53% had BTKi refractory disease, 23% had TP53 mutation, and 8% had secondary CNS lymphoma. Median (range) on-study follow-up was 16.1 months (0.4-60.5). In the efficacy set (n = 83; DL1 + DL2), ORR was 83.1% (95% CI, 73.3 to 90.5) and complete response (CR) rate was 72.3% (95% CI, 61.4 to 81.6). Median duration of response was 15.7 months (95% CI, 6.2 to 24.0) and progression-free survival was 15.3 months (95% CI, 6.6 to 24.9). Most common grade ≥3 treatment-emergent AEs were neutropenia (56%), anemia (37.5%), and thrombocytopenia (25%). Cytokine release syndrome (CRS) was reported in 61% of patients (grade 3/4, 1%; grade 5, 0), neurologic events (NEs) in 31% (grade 3/4, 9%; grade 5, 0), grade ≥3 infections in 15%, and prolonged cytopenia in 40%. CONCLUSION: Liso-cel demonstrated high CR rate and deep, durable responses with low incidence of grade ≥3 CRS, NE, and infections in patients with heavily pretreated R/R MCL, including those with high-risk, aggressive disease.
引用
- Wang M, Siddiqi T, Gordon LI, et al. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol. 2023. PMID: 38072625. doi:10.1200/JCO.23.02214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。